undamentalytics Newsletter
Sign in

Revolution Medicines, Inc. cash flow statement

In fiscal 2025, Revolution Medicines, Inc.'s operations generated −$898m of cash; it spent $16.0m on capital projects, leaving free cash flow of −$914m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash from operations1−50−100−147−224−351−557−898
Depreciation and amortisation22334578
Stock-based pay13921316279118
Capital spending13371181016
Free cash flow−0−52−103−154−235−358−568−914
Free cash flow after stock pay−1−55−112−174−266−420−647−1,032
Dividends paid——0—————
Shares issued——4202812483247280

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Revolution Medicines, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Revolution Medicines, Inc.